2D-DIGE analysis of sera from transgenic mouse models reveals novel candidate protein biomarkers for human gastric cancer

Journal of Proteomics

Volumn 77, Issue , 2012, Pages 40-58

  Penno, Megan A S ^a   Klingler Hoffmann, Manuela ^a   Brazzatti, Julie A ^a,e   Boussioutas, Alex ^b,c   Putoczki, Tracy ^d   Ernst, Matthias ^d   Hoffmann, Peter ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

2D DIGE; Biomarkers; Early detection; Gastric cancer; Mouse models; Translational proteomics

Indexed keywords

AFAMIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CLUSTERIN; HAPTOGLOBIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; STOMACH CANCER; TRANSGENIC MOUSE; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

AGED; ANIMALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PROTEOME; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

MURINAE; MUS; MUS MUSCULUS;

EID: 84870379390     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.07.002     Document Type: Article

References (65)

1. Brenner H., Rothenbacher D., Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009, 472:467-477.
2. Layke J.C., Lopez P.P. Gastric cancer: diagnosis and treatment options. Am Fam Physician 2004, 69:1133-1140.
3. Hamashima C., Shibuya D., Yamazaki H., Inoue K., Fukao A., Saito H., et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008, 38:259-267.
4. Tsubono Y., Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer 2000, 3:9-18.
5. Tashiro A., Sano M., Kinameri K., Fujita K., Takeuchi Y. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol 2006, 12:4873-4874.
6. Marrelli D., Roviello F., De Stefano A., Farnetani M., Garosi L., Messano A., et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999, 57:55-62.
7. Takahashi Y., Takeuchi T., Sakamoto J., Touge T., Mai M., Ohkura H., et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 2003, 6:142-145.
8. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006, 9:245-253.
9. Ang T.L., Fock K.M., Dhamodaran S., Teo E.K., Tan J. Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian population. J Gastroenterol Hepatol 2005, 20:1603-1609.
10. Surinova S., Schiess R., Huttenhain R., Cerciello F., Wollscheid B., Aebersold R. On the development of plasma protein biomarkers. J Proteome Res 2011, 10:5-16.
11. Kelly-Spratt K.S., Kasarda A.E., Igra M., Kemp C.J. A mouse model repository for cancer biomarker discovery. J Proteome Res 2008, 7:3613-3618.
12. Jenkins B.J., Grail D., Nheu T., Najdovska M., Wang B., Waring P., et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 2005, 11:845-852.
13. Tebbutt N.C., Giraud A.S., Inglese M., Jenkins B., Waring P., Clay F.J., et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002, 8:1089-1097.
14. Ernst M., Jenkins B.J. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 2004, 20:23-32.
15. Correa P., Haenszel W., Cuello C., Tannenbaum S., Archer M. A model for gastric cancer epidemiology. Lancet 1975, 2:58-60.
16. Ernst M., Najdovska M., Grail D., Lundgren-May T., Buchert M., Tye H., et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008, 118:1727-1738.
17. Judd L.M., Ulaganathan M., Howlett M., Giraud A.S. Cytokine signalling by gp130 regulates gastric mucosal healing after ulceration and, indirectly, antral tumour progression. J Pathol 2009, 217:552-562.
18. Penno M., Ernst M., Hoffmann P. Comparative 2D DIGE Analysis of the Depleted Serum Proteome for Biomarker Discovery. Methods Mol Biol 2012, 854:207-220.
19. Lenth R.V. Statistical power calculations. J Anim Sci 2007, 85:E24-E29.
20. Penno M.A., Bacic A., Colegate S.M., Hoffmann P., Michalski W.P. Identifying candidate serum biomarkers of exposure to tunicamycins in rats using two-dimensional electrophoresis. J Proteome Res 2009, 8:2812-2826.
21. Karp N.A., Lilley K.S. Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes. Proteomics 2005, 5:3105-3115.
22. Karp N.A., McCormick P.S., Russell M.R., Lilley K.S. Experimental and statistical considerations to avoid false conclusions in proteomics studies using differential in-gel electrophoresis. Mol Cell Proteomics 2007, 6:1354-1364.
23. Storey J.D., Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003, 100:9440-9445.
24. Kopetz V.A., Penno M.A., Hoffmann P., Wilson D.P., Beltrame J.F. Potential mechanisms of the acute coronary syndrome presentation in patients with the coronary slow flow phenomenon - insight from a plasma proteomic approach. Int J Cardiol Apr 5 2012, 156(1):84-91.
25. Ishihama Y., Oda Y., Tabata T., Sato T., Nagasu T., Rappsilber J., et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 2005, 4:1265-1272.
26. Faca V.M., Song K.S., Wang H., Zhang Q., Krasnoselsky A.L., Newcomb L.F., et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008, 5:e123.
27. Ucar E., Semerci E., Ustun H., Yetim T., Huzmeli C., Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008, 25:1075-1084.
28. Hung K.E., Faca V., Song K., Sarracino D.A., Richard L.G., Krastins B., et al. Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila) 2009, 2:224-233.
29. Pitteri S.J., Faca V.M., Kelly-Spratt K.S., Kasarda A.E., Wang H., Zhang Q., et al. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res 2008, 7:1481-1489.
30. Pitteri S.J., JeBailey L., Faca V.M., Thorpe J.D., Silva M.A., Ireton R.C., et al. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One 2009, 4:e7916.
31. Ritorto M.S., Borlak J. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies. J Proteome Res 2011, 10:3012-3030.
32. Cima I., Schiess R., Wild P., Kaelin M., Schuffler P., Lange V., et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci U S A 2011, 108:3342-3347.
33. Taguchi A., Politi K., Pitteri S.J., Lockwood W.W., Faca V.M., Kelly-Spratt K., et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011, 20:289-299.
34. Chong P.K., Lee H., Zhou J., Liu S.C., Loh M.C., So J.B., et al. Reduced plasma APOA1 level is associated with gastric tumor growth in MKN45 mouse xenograft model. J Proteomics 2010, 73:1632-1640.
35. Chong P.K., Lee H., Zhou J., Liu S.C., Loh M.C., Wang T.T., et al. ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res 2010, 9:3671-3679.
36. Juan H.F., Chen J.H., Hsu W.T., Huang S.C., Chen S.T., Yi-Chung Lin J., et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 2004, 4:2766-2775.
37. Lam K.W., Lo S.C. Discovery of diagnostic serum biomarkers of gastric cancer using proteomics. Proteomics Clin Appl 2008, 2:219-228.
38. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342.
39. Rifai N., Silverman L.M. A simple immunotechnique for the determination of serum concentration of apolipoprotein-E. Clin Chim Acta 1987, 163:207-213.
40. Souza D.R., Nakazone M.A., Pinhel M.A., Alvares R.M., Monaco A.C., Pinheiro A., et al. Association between apolipoprotein E genotype, serum lipids, and colorectal cancer in Brazilian individuals. Braz J Med Biol Res 2009, 42:397-403.
41. De Feo E., Rowell J., Cadoni G., Nicolotti N., Arzani D., Giorgio A., et al. A case-control study on the effect of apoliprotein E genotype on head and neck cancer risk. Cancer Epidemiol Biomarkers Prev 2010, 19:2839-2846.
42. Grant W.B. A multicountry ecological study of risk-modifying factors for prostate cancer: apolipoprotein E epsilon4 as a risk factor and cereals as a risk reduction factor. Anticancer Res 2010, 30:189-199.
43. Opstal-van Winden A.W., Krop E.J., Karedal M.H., Gast M.C., Lindh C.H., Jeppsson M.C., et al. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer 2011, 11:381.
44. Sakashita K., Tanaka F., Zhang X., Mimori K., Kamohara Y., Inoue H., et al. Clinical significance of ApoE expression in human gastric cancer. Oncol Rep 2008, 20:1313-1319.
45. Chen Y.C., Pohl G., Wang T.L., Morin P.J., Risberg B., Kristensen G.B., et al. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 2005, 65:331-337.
46. Craig W.Y., Ledue T.B., Ritchie R.F. Plasma Proteins: Clinical Utility and Interpretation 2001, Foundation for Blood Research, Scarborough, MA.
47. Ngure R.M., David Eckersall P., Jennings F.W., Burke J.M., Stear M.J., Kennedy P.G.E., et al. Major acute phase response of haptoglobin and serum amyloid-P following experimental infection of mice with Trypanosoma brucei brucei. Parasitol Int 1997, 46:247-254.
48. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997, 181:257-266.
49. Grigorov I., Lazic T., Cvetkovic I., Milosavljevic T., Petrovic M. STAT3 involvement in the acute phase-related expression of the rat haptoglobin gene. Mol Biol Rep 2000, 27:81-86.
50. Zhang Z., Bast R.C., Yu Y., Li J., Sokoll L.J., Rai A.J., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890.
51. Dieplinger H., Ankerst D.P., Burges A., Lenhard M., Lingenhel A., Fineder L., et al. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:1127-1133.
52. Jackson D., Craven R.A., Hutson R.C., Graze I., Lueth P., Tonge R.P., et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007, 13:7370-7379.
53. Wu C.C., Peng P.H., Chang Y.T., Huang Y.S., Chang K.P., Hao S.P., et al. Identification of potential serum markers for nasopharyngeal carcinoma from a xenografted mouse model using Cy-dye labeling combined with three-dimensional fractionation. Proteomics 2008, 8:3605-3620.
54. de Silva H.V., Harmony J.A., Stuart W.D., Gil C.M., Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry 1990, 29:5380-5389.
55. Morrissey C., Lakins J., Moquin A., Hussain M., Tenniswood M. An antigen capture assay for the measurement of serum clusterin concentrations. J Biochem Biophys Methods 2001, 48:13-21.
56. Jenne D.E., Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 1992, 17:154-159.
57. Trougakos I.P., Gonos E.S. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002, 34:1430-1448.
58. Kang H.C., Kim I.J., Park J.H., Shin Y., Ku J.L., Jung M.S., et al. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004, 10:272-284.
59. Bi J., Guo A.L., Lai Y.R., Li B., Zhong J.M., Wu H.Q., et al. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. Neoplasma 2010, 57:191-197.
60. Rizzi F., Bettuzzi S. The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer 2010, 17:R1-R17.
61. Lefebvre O., Chenard M.P., Masson R., Linares J., Dierich A., LeMeur M., et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996, 274:259-262.
62. Xu X., Brodie S.G., Yang X., Im Y.H., Parks W.T., Chen L., et al. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 2000, 19:1868-1874.
63. Wang T.C., Dangler C.A., Chen D., Goldenring J.R., Koh T., Raychowdhury R., et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000, 118:36-47.
64. Tu S., Bhagat G., Cui G., Takaishi S., Kurt-Jones E.A., Rickman B., et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14:408-419.
65. Li Q.L., Ito K., Sakakura C., Fukamachi H., Inoue K., Chi X.Z., et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002, 109:113-124.